TY - JOUR
T1 - Precision Medicine in Myeloma
T2 - Challenges in Defining an Actionable Approach
AU - González-Calle, Verónica
AU - Keane, Niamh
AU - Braggio, Esteban
AU - Fonseca, Rafael
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/10
Y1 - 2017/10
N2 - Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.
AB - Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.
KW - Actionable mutation
KW - Driver
KW - Immunotherapy
KW - Multiple myeloma
KW - Target therapy
UR - http://www.scopus.com/inward/record.url?scp=85025107555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025107555&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2017.06.021
DO - 10.1016/j.clml.2017.06.021
M3 - Review article
C2 - 28743429
AN - SCOPUS:85025107555
SN - 2152-2650
VL - 17
SP - 621
EP - 630
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 10
ER -